Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology

Tandem Diabetes Care (Nasdaq:TNDM) can bring its miniature insulin pump to more customers following a new regulatory nod.

Our sister site, Drug Delivery Business Newsreports today that Tandem picked up CE mark for its Mobi pump with Control-IQ+ technology.

In an SEC filing, the company said it intends to pursue additional regulatory and pre-commercial activities now. That includes securing in-country registrations and reimbursement for Mobi in European markets. It then plans to begin its European commercial rollouts by the end of 2025.

Sign up for Blog Updates